The LD50 in rat following oral and intraperitoneal administration is 3370 mg/kg and 805 mg/kg, respectively MSDS. Subcutaneous LD50 in mouse is >5000 mg/kg MSDS. Mild skin irritation was seen in rabbits following dermal application of 750 mg/30d(l) MSDS. Non-steroidal anti-inflammatory drug (NSAID) overdose may produce nausea, vomiting, indigestion and upper abdominal pain. Other effects may include drowsiness, dizziness, confusion, disorientation, lethargy MSDS.
Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac. It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, and itching. It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization A32822. Bufexamac was also withdrawn by the EMA in April 2010.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aminosalicylic acid | The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Bufexamac. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Bufexamac. |
| Sulfasalazine | The therapeutic efficacy of Sulfasalazine can be decreased when used in combination with Bufexamac. |
| Diflunisal | The therapeutic efficacy of Diflunisal can be decreased when used in combination with Bufexamac. |
| Acetylsalicylic acid | The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Bufexamac. |
| Balsalazide | The therapeutic efficacy of Balsalazide can be decreased when used in combination with Bufexamac. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Bufexamac is combined with Olsalazine. |
| Bismuth subsalicylate | The therapeutic efficacy of Bismuth subsalicylate can be decreased when used in combination with Bufexamac. |
| Dersalazine | The therapeutic efficacy of Dersalazine can be decreased when used in combination with Bufexamac. |
| Phenyl aminosalicylate | The therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Bufexamac. |
| Methyl salicylate | The therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Bufexamac. |
| Trolamine salicylate | The therapeutic efficacy of Trolamine salicylate can be decreased when used in combination with Bufexamac. |
| Nitroaspirin | The therapeutic efficacy of Nitroaspirin can be decreased when used in combination with Bufexamac. |
| Aloxiprin | The therapeutic efficacy of Aloxiprin can be decreased when used in combination with Bufexamac. |
| Guacetisal | The therapeutic efficacy of Guacetisal can be decreased when used in combination with Bufexamac. |
| Carbaspirin calcium | The therapeutic efficacy of Carbaspirin calcium can be decreased when used in combination with Bufexamac. |
| Choline salicylate | The therapeutic efficacy of Choline salicylate can be decreased when used in combination with Bufexamac. |
| Thiosalicylic acid | The therapeutic efficacy of Thiosalicylic acid can be decreased when used in combination with Bufexamac. |
| Diclofenac | The risk or severity of adverse effects can be increased when Diclofenac is combined with Bufexamac. |
| Flurbiprofen | The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bufexamac. |
| Bromfenac | The risk or severity of adverse effects can be increased when Bromfenac is combined with Bufexamac. |
| Nepafenac | The risk or severity of adverse effects can be increased when Nepafenac is combined with Bufexamac. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Bufexamac. |
| Nabumetone | The risk or severity of adverse effects can be increased when Nabumetone is combined with Bufexamac. |
| Tenoxicam | The risk or severity of adverse effects can be increased when Tenoxicam is combined with Bufexamac. |
| Celecoxib | The risk or severity of adverse effects can be increased when Celecoxib is combined with Bufexamac. |
| Tolmetin | The risk or severity of adverse effects can be increased when Tolmetin is combined with Bufexamac. |
| Rofecoxib | The risk or severity of adverse effects can be increased when Rofecoxib is combined with Bufexamac. |
| Piroxicam | The risk or severity of adverse effects can be increased when Piroxicam is combined with Bufexamac. |
| Fenoprofen | The risk or severity of adverse effects can be increased when Fenoprofen is combined with Bufexamac. |
| Valdecoxib | The risk or severity of adverse effects can be increased when Valdecoxib is combined with Bufexamac. |
| Sulindac | The risk or severity of adverse effects can be increased when Sulindac is combined with Bufexamac. |
| Etodolac | The risk or severity of adverse effects can be increased when Etodolac is combined with Bufexamac. |
| Mefenamic acid | The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Bufexamac. |
| Naproxen | The risk or severity of adverse effects can be increased when Naproxen is combined with Bufexamac. |
| Phenylbutazone | The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bufexamac. |
| Meloxicam | The risk or severity of adverse effects can be increased when Meloxicam is combined with Bufexamac. |
| Carprofen | The risk or severity of adverse effects can be increased when Carprofen is combined with Bufexamac. |
| Suprofen | The risk or severity of adverse effects can be increased when Suprofen is combined with Bufexamac. |
| Salicylic acid | The risk or severity of adverse effects can be increased when Salicylic acid is combined with Bufexamac. |
| Meclofenamic acid | The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bufexamac. |
| Oxaprozin | The risk or severity of adverse effects can be increased when Oxaprozin is combined with Bufexamac. |
| Ketoprofen | The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bufexamac. |
| Ibuprofen | The risk or severity of adverse effects can be increased when Ibuprofen is combined with Bufexamac. |
| Lumiracoxib | The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Bufexamac. |
| Magnesium salicylate | The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bufexamac. |
| Salsalate | The risk or severity of adverse effects can be increased when Salsalate is combined with Bufexamac. |
| Choline magnesium trisalicylate | The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bufexamac. |
| Antipyrine | The risk or severity of adverse effects can be increased when Antipyrine is combined with Bufexamac. |
| Tiaprofenic acid | The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Bufexamac. |
| Etoricoxib | The risk or severity of adverse effects can be increased when Etoricoxib is combined with Bufexamac. |
| Oxyphenbutazone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bufexamac. |
| Niflumic acid | The risk or severity of adverse effects can be increased when Niflumic acid is combined with Bufexamac. |
| Nimesulide | The risk or severity of adverse effects can be increased when Nimesulide is combined with Bufexamac. |
| Benoxaprofen | The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bufexamac. |
| Zomepirac | The risk or severity of adverse effects can be increased when Zomepirac is combined with Bufexamac. |
| Lornoxicam | The risk or severity of adverse effects can be increased when Lornoxicam is combined with Bufexamac. |
| Aceclofenac | The risk or severity of adverse effects can be increased when Aceclofenac is combined with Bufexamac. |
| Zaltoprofen | The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bufexamac. |
| Azapropazone | The risk or severity of adverse effects can be increased when Azapropazone is combined with Bufexamac. |
| Felbinac | The risk or severity of adverse effects can be increased when Felbinac is combined with Bufexamac. |
| Parecoxib | The risk or severity of adverse effects can be increased when Parecoxib is combined with Bufexamac. |
| Salicylamide | The risk or severity of adverse effects can be increased when Salicylamide is combined with Bufexamac. |
| Kebuzone | The risk or severity of adverse effects can be increased when Kebuzone is combined with Bufexamac. |
| Isoxicam | The risk or severity of adverse effects can be increased when Isoxicam is combined with Bufexamac. |
| Indoprofen | The risk or severity of adverse effects can be increased when Indoprofen is combined with Bufexamac. |
| Ibuproxam | The risk or severity of adverse effects can be increased when Ibuproxam is combined with Bufexamac. |
| Floctafenine | The risk or severity of adverse effects can be increased when Floctafenine is combined with Bufexamac. |
| Fenbufen | The risk or severity of adverse effects can be increased when Fenbufen is combined with Bufexamac. |
| Etofenamate | The risk or severity of adverse effects can be increased when Etofenamate is combined with Bufexamac. |
| Epirizole | The risk or severity of adverse effects can be increased when Epirizole is combined with Bufexamac. |
| Loxoprofen | The risk or severity of adverse effects can be increased when Loxoprofen is combined with Bufexamac. |
| Droxicam | The risk or severity of adverse effects can be increased when Droxicam is combined with Bufexamac. |
| Tolfenamic acid | The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Bufexamac. |
| Clonixin | The risk or severity of adverse effects can be increased when Clonixin is combined with Bufexamac. |
| Propacetamol | The risk or severity of adverse effects can be increased when Propacetamol is combined with Bufexamac. |
| Tepoxalin | The risk or severity of adverse effects can be increased when Tepoxalin is combined with Bufexamac. |
| Flunixin | The risk or severity of adverse effects can be increased when Flunixin is combined with Bufexamac. |
| Indobufen | The risk or severity of adverse effects can be increased when Indobufen is combined with Bufexamac. |
| Tinoridine | The risk or severity of adverse effects can be increased when Tinoridine is combined with Bufexamac. |
| Alclofenac | The risk or severity of adverse effects can be increased when Alclofenac is combined with Bufexamac. |
| Fentiazac | The risk or severity of adverse effects can be increased when Fentiazac is combined with Bufexamac. |
| Suxibuzone | The risk or severity of adverse effects can be increased when Suxibuzone is combined with Bufexamac. |
| Bumadizone | The risk or severity of adverse effects can be increased when Bumadizone is combined with Bufexamac. |
| Alminoprofen | The risk or severity of adverse effects can be increased when Alminoprofen is combined with Bufexamac. |
| Feprazone | The risk or severity of adverse effects can be increased when Bufexamac is combined with Feprazone. |
| Difenpiramide | The risk or severity of adverse effects can be increased when Bufexamac is combined with Difenpiramide. |
| Nifenazone | The risk or severity of adverse effects can be increased when Bufexamac is combined with Nifenazone. |
| Lonazolac | The risk or severity of adverse effects can be increased when Bufexamac is combined with Lonazolac. |
| Tenidap | The risk or severity of adverse effects can be increased when Bufexamac is combined with Tenidap. |
| Bendazac | The risk or severity of adverse effects can be increased when Bufexamac is combined with Bendazac. |
| Pranoprofen | The risk or severity of adverse effects can be increased when Bufexamac is combined with Pranoprofen. |
| Propyphenazone | The risk or severity of adverse effects can be increased when Bufexamac is combined with Propyphenazone. |
| Proglumetacin | The risk or severity of adverse effects can be increased when Bufexamac is combined with Proglumetacin. |
| Ethenzamide | The risk or severity of adverse effects can be increased when Bufexamac is combined with Ethenzamide. |
| Mofebutazone | The risk or severity of adverse effects can be increased when Bufexamac is combined with Mofebutazone. |
| Proquazone | The risk or severity of adverse effects can be increased when Bufexamac is combined with Proquazone. |
| Benorilate | The risk or severity of adverse effects can be increased when Bufexamac is combined with Benorilate. |
| Pirprofen | The risk or severity of adverse effects can be increased when Bufexamac is combined with Pirprofen. |
| Acemetacin | The risk or severity of adverse effects can be increased when Bufexamac is combined with Acemetacin. |